Blinatumomab has promising effect on hard-to-treat, rare acute lymphoblastic leukaemia subtype
Blinatumomab has promising effect on hard-to-treat, rare acute lymphoblastic leukaemia subtype
Rituximab plus chemotherapy improves outcomes in acute lymphoblastic leukaemia
First all-oral treatment for relapsed and treatment-resistant multiple myeloma
Experimental oral therapy for high-risk CLL shows promise
Ibrutinib to treat elderly patients with chronic lymphocytic leukaemia
Idelalisib combination therapy in relapsed or treatment-resistant CLL better than standard regimen
ASH 2015: Novel combination approaches for multiple myeloma
ASH 2015: Ibrutinib as first-line treatment for chronic lymphocytic leukaemia
ASH 2015: New targeted therapies for haematological malignancies
Using epigenetics to manipulate cancer cells
Overcoming the barriers of the P53 dysfunction to cure blood cancers
Exciting new immunosuppressive therapy treatment for aplastic anaemia